Stereotactic MR-guided Adaptive Radiation Therapy Research Articles

Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Tumors

Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Tumors

Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer

Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer

Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer

Background and purposeTo implement a robust and fast stereotactic MR-guided adaptive radiation therapy (SMART) online strategy in locally advanced pancreatic cancer (LAPC). Material and methodsSMART strategy for plan adaptation was implemented with the MRIdian system (ViewRay Inc.). At each fraction, OAR (re-)contouring is done within a distance of 3cm from the PTV surface. Online plan re-optimization is based on robust prediction of OAR dose and optimization objectives, obtained by building an artificial neural network (ANN). Proposed limited re-contouring strategy for plan adaptation (SMART3CM) is evaluated by comparing 50 previously delivered fractions against a standard (re-)planning method using full-scale OAR (re-)contouring (FULLOAR). Plan quality was assessed using PTV coverage (V95%, Dmean, D1cc) and institutional OAR constraints (e.g. V33Gy). ResultsSMART3CM required a significant lower number of optimizations than FULLOAR (4 vs 18 on average) to generate a plan meeting all objectives and institutional OAR constraints. PTV coverage with both strategies was identical (mean V95%=89%). Adaptive plans with SMART3CM exhibited significant lower intermediate and high doses to all OARs than FULLOAR, which also failed in 36% of the cases to adhere to the V33Gy dose constraint. ConclusionsSMART3CM approach for LAPC allows good OAR sparing and adequate target coverage while requiring only limited online (re-)contouring from clinicians.

OC-0425: Clinical experience with stereotactic MR-guided adaptive radiation therapy for pancreatic tumors

Purpose or Objective The duodenum is the primary dose-limiting organ when performing SBRT for locally advanced pancreatic cancer (LAPC). With technical and imaging advancements, the incidence of grade ≥3 small bowel toxicity (bleeding, perforation, strictures) has decreased to